User Fees

The chances of drug tracking measures being included in the broader FDA user fee/reform package appeared to wane this week in both chambers of Congress. A House Energy and Commerce lawmaker who backs drug tracking initiatives, including an industry-backed drug proposal, clashed with FDA's top drug official who said the industry plan would not prevent counterfeit and adulterated drugs from reaching patients and therefore would not solve the problem stakeholders are trying to address.

Infectious disease experts believe their best chance of getting a recently proposed limited population approval mechanism into FDA user fee legislation is to focus on the plan's benefits in spurring new antibiotics, even though the idea has been discussed for broader uses such as obesity drugs. The Infectious Diseases Society of America is touting support from a slew of drug companies and public health groups as it ramps up lobby efforts in support of the limited approval proposal.

Congressional committees working on the reauthorization of FDA user fees, including a fee for the health reform-created biosimilars review pathway, could begin marking up bills the last week in April, sources said, with the Senate health committee planning to convene a markup the week of April 23. A bipartisan draft is expected from the House Energy and Commerce Committee in the coming weeks, a source said, noting that both chambers still have to address gaps in their legislative measures.